The hepatocyte and the cancer cell: Dr Jekyll and Mr Hyde

The Liver: Biology and Pathobiology

Volumn , Issue , 2009, Pages 1075-1090

  Gillet, Jean Pierre ^a   Gottesman, Michael M ^a   Okabe, Mitsunori ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875997848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470747919.ch66     Document Type: Chapter

References (168)

1. Alrefai, W.A. and Gill, R.K. (2007) Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res, 24, 1803-23.
2. Alisi, A. and Balsano, C. (2007) Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. Nutr Rev, 65, 550-53.
3. Li, B., Ye, T., Zhao, L. et al. (2006) Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells. Hepatobiliary Pancreat Dis Int, 5, 552-59.
4. Tien Kuo, M. and Savaraj, N. (2006) Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog, 45, 701-9.
5. Tillmann, H.L. (2007) Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol, 13, 125-40.
6. Koev, G. and Kati, W. (2008) The emerging field of HCV drug resistance. Expert Opin Investig Drugs, 17, 303-19.
7. Huang, Y. and Sadee, W. (2006) Membrane transporters and channels in chemoresistance and sensitivity of tumor cells. Cancer Lett, 239, 168-82.
8. Jigorel, E., Le Vee, M., Boursier-Neyret, C., Parmentier, Y. and Fardel, O. (2006) Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos, 34, 1756-63.
9. Iyanagi, T. (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxification. Int Rev Cytol, 260, 35-112.
10. Kimchi-Sarfaty, C., Oh, J.M., Kim, I.W. et al. (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science, 315, 525-28.
11. Miller, C.R. and McLeod, H.L. (2007) Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol, 5, 9-14.
12. Sauna, Z.E., Kimchi-Sarfaty, C., Ambudkar, S.V. and Gottesman, M.M. (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res, 67, 9609-12.
13. Gillet, J.P., Efferth, T. and Remacle, J. (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta, 1775, 237-62.
14. Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. and Gottesman, M.M. (2006) Targeting multidrug resistance in cancer. Nat Rev Cancer, 5, 219-34.
15. Longley, D.B. and Johnston, P.G. (2005) Molecular mechanisms of drug resistance. J Pathol, 205, 275-92.
16. Geigl, J.B., Obenauf, A.C., Schwarzbraun, T. and Speicher, M.R. (2008) Defining ‘chromosomal instability’. Trends Genet, 24, 64-69.
17. Herath, N.I., Leggett, B.A. and MacDonald, G.A. (2006) Review of genetic and epigenetic alterations in hepatocarcinogenesis. J Gastroenterol Hepatol, 21, 15-21.
18. Daly, A.K. (2004) Pharmacogenetics of the cytochromes P450. Curr Top Med Chem, 4, 1733-44.
19. Lobrich, M. and Jeggo, P.A. (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer, 7, 861-69.
20. Juliano, R.L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta, 455, 152-62.
21. Sauna, Z.E., Kim, I.W. and Ambudkar, S.V. (2007) Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr, 39, 481-87.
22. Hediger, M.A., Romero, M.F., Peng, J.B., Rolfs, A., Takanaga, H. and Bruford, E.A. (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins introduction. Pflugers Arch, 447, 465-68.
23. Shitara, Y., Sato, H. and Sugiyama, Y. (2005) Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol, 45, 689-723.
24. Meier, P.J. and Stieger, B. (2002) Bile salt transporters. Annu Rev Physiol, 64, 635-61.
25. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. and Abe, T. (2004) The organic anion transporter (OATP) family. Drug Metab Pharmacokinet, 19, 171-79.
26. Hagenbuch, B. and Meier, P.J. (2004) Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch, 447, 653-65.
27. Abe, T., Kakyo, M., Tokui, T. et al. (1999) Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem, 274, 17159-63.
28. Abe, T., Unno, M., Onogawa, T. et al. (2001) LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 120, 1689-99.
29. Kullak-Ublick, G.A., Ismair, M.G., Stieger, B. et al. (2001) Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology, 120, 525-33.
30. Koepsell, H. and Endou, H. (2004) The SLC22 drug transporter family. Pflugers Arch, 447, 666-76.
31. Hall, M.D., Okabe, M., Shen, D.W., Liang, X.J. and Gottesman, M.M. (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol, 48, 495-535.
32. Suchy, F.J. and Ananthanarayanan, M. (2006) Bile salt excretory pump: biology and pathobiology. J Pediatr Gastroenterol Nutr, 43 (Suppl 1), S10-16.
33. Stieger, B., Meier, Y. and Meier, P.J. (2007) The bile salt export pump. Pflugers Arch, 453, 611-20.
34. Oude Elferink, R.P. and Paulusma, C.C. (2007) Function and pathophysiological importance of ABCB4 (MDR3P-glycoprotein). Pflugers Arch, 453, 601-10.
35. Nies, A.T. and Keppler, D. (2007) The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch, 453, 643-59.
36. Wang, J., Sun, F., Zhang, D.W. et al. (2006) Sterol transfer by ABCG5 and ABCG8: in vitro assay and reconstitution. J Biol Chem, 281, 27894-904.
37. Wang, J., Zhang, D.W., Lei, Y. et al. (2008) Purification and reconstitution of sterol transfer by native mouse ABCG5 and ABCG8. Biochemistry, 47, 5194-204.
38. Callaghan, R., Crowley, E., Potter, S. and Kerr, I.D. (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol, 48, 365-78.
39. Polgar, O., Robey, R.W. and Bates, S.E. (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol, 4, 1-15.
40. Guminski, A.D., Balleine, R.L., Chiew, Y.E. et al. (2006) MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol Oncol, 100, 239-46.
41. Materna, V., Stege, A., Surowiak, P., Priebsch, A. and Lage, H. (2006) RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun, 348, 153-57.
42. Roelofsen, H., Muller, M. and Jansen, P.L. (1997) Regulation of organic anion transport in the liver. Yale J Biol Med, 70, 435-45.
43. Flens, M.J., Zaman, G.J., van der Valk, P. et al. (1996) Tissue distribution of the multidrug resistance protein. Am J Cardiovasc Pathol, 148, 1237-47.
44. Deeley, R.G., Westlake, C. and Cole, S.P. (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev, 86, 849-99.
45. Chen, Z.S., Guo, Y., Belinsky, M.G., Kotova, E. and Kruh, G.D. (2005) Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol, 67, 545-57.
46. Bera, T.K., Lee, S., Salvatore, G., Lee, B. and Pastan, I. (2001) MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med, 7, 509-16.
47. Yabuuchi, H., Shimizu, H., Takayanagi, S. and Ishikawa, T. (2001) Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun, 288, 933-39.
48. Zelcer, N., Reid, G., Wielinga, P. et al. (2003) Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J, 371, 361-67.
49. Brown, C.M., Reisfeld, B. and Mayeno, A.N. (2008) Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metab Rev, 40, 1-100.
50. Ghezzi, P. and Di Simplicio, P. (2007) Glutathionylation pathways in drug response. Curr Opin Pharmacol, 7, 398-403.
51. Hemmerich, S., Verdugo, D. and Rath, V.L. (2004) Strategies for drug discovery by targeting sulfation pathways. Drug Discov Today, 9, 967-75.
52. Nakata, K., Tanaka, Y., Nakano, T. et al. (2006) Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems. Drug Metab Pharmacokinet, 21, 437-57.
53. Pal, D. and Mitra, A.K. (2006) MDR- and CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol, 1, 323-39.
54. Zhou, S., Chan, S.Y., Goh, B.C. et al. (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet, 44, 279-304.
55. Katoh, M., Nakajima, M., Yamazaki, H. and Yokoi, T. (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci, 12, 505-13.
56. Catania, V.A., Sanchez Pozzi, E.J., Luquita, M.G. et al. (2004) Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein 2. Ann Hepatol, 3, 11-17.
57. Nies, A.T., Schwab, M. and Keppler, D. (2008) Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin Drug Metab Toxicol, 4, 545-68.
58. Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
59. El-Serag, H.B. and Rudolph, K.L. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76.
60. Schwartz, M., Roayaie, S. and Konstadoulakis, M. (2007) Strategies for the management of hepatocellular carcinoma. Nat Clin Pract, 4, 424-32.
61. Llovet, J.M. and Bruix, J. (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 48 (Suppl 1), S20-37.
62. Cillo, U., Vitale, A., Bassanello, M. et al. (2004) Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg, 239, 150-59.
63. Wong, S.N., Lin, C.J., Lin, C.C., Chen, W.T., Cua, I.H. and Lin, S.M. (2008) Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am J Roentgenol, 190, W187-95.
64. Garrean, S., Hering, J., Saied, A., Helton, W.S. and Espat, N.J. (2008) Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg, 195, 508-20.
65. Marelli, L., Stigliano, R., Triantos, C. et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol, 30, 6-25.
66. Llovet, J.M. and Bruix, J. (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 37, 429-42.
67. Zhu, A.X. (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist, 11, 790-800.
68. Lang, L. (2008) FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology, 134, 379.
69. Llovet, J.M., Ricci, S., Mazzaferro, V. et al. (2007) Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 25, LBA1.
70. Alizadeh, A.A., Eisen, M.B., Davis, R.E. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403, 503-11.
71. Rosenwald, A., Wright, G., Wiestner, A. et al. (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3, 185-97.
72. Stratowa, C., Loffler, G., Lichter, P. et al. (2001) CDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. Int J Cancer, 91, 474-80.
73. Golub, T.R., Slonim, D.K., Tamayo, P. et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286, 531-37.
74. Dunphy, C.H. (2006) Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch Pathol Lab Med, 130, 483-520.
75. Thorgeirsson, S.S., Lee, J.S. and Grisham, J.W. (2006) Molecular prognostication of liver cancer: end of the beginning. J Hepatol, 44, 798-805.
76. Quackenbush, J. (2006) Microarray analysis and tumor classification. N Engl J Med, 354, 2463-72.
77. Llovet, J.M., Bru, C. and Bruix, J. (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 19, 329-38.
78. Chevret, S., Trinchet, J.C., Mathieu, D., Rached, A.A., Beaugrand, M. and Chastang, C. (1999) A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol, 31, 133-41.
79. Kudo, M., Chung, H. and Osaki, Y. (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol, 38, 207-15.
80. Marrero, J.A. (2006) Staging systems for hepatocellular carcinoma: should we all use the BCLC system? J Hepatol, 44, 630-32.
81. Marrero, J.A., Fontana, R.J., Barrat, A. et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (Baltimore), 41, 707-16.
82. Guglielmi, A., Ruzzenente, A., Pachera, S. et al. (2008) Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol, 103, 597-604.
83. Camma, C., Di Marco, V., Cabibbo, G. et al. (2008) Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Aliment Pharmacol Ther, 28, 62-75.
84. Collette, S., Bonnetain, F., Paoletti, X. et al. (2008) Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol, 19, 1117-26.
85. Chung, H., Kudo, M., Takahashi, S. et al. (2008) Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona clinic liver cancer staging classification, and Tokyo score. J Gastroenterol Hepatol, 23, 445-52.
86. Kondo, K., Chijiiwa, K., Nagano, M. et al. (2007) Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology, 54, 1534-38.
87. Seo, Y.S., Kim, Y.J., Um, S.H. et al. (2008) Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol, 23, 1267-75.
88. Laurent-Puig, P., Legoix, P., Bluteau, O. et al. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 120, 1763-73.
89. Boyault, S., Rickman, D.S., de Reynies, A. et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 45, 42-52.
90. Ye, Q.H., Qin, L.X., Forgues, M. et al. (2003) Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 9, 416-23.
91. Budhu, A., Jia, H.L., Forgues, M. et al. (2008) Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (Baltimore), 47, 897-907.
92. Jiang, J., Gusev, Y., Aderca, I. et al. (2008) Association of microRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 14, 419-27.
93. Lee, J.S., Chu, I.S., Heo, J. et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology, 40, 667-76.
94. Wurmbach, E., Chen, Y.B., Khitrov, G. et al. (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology, 45, 938-47.
95. Villanueva, A., Toffanin, S. and Llovet, J.M. (2008) Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol, 20, 444-53.
96. Iizuka, N., Hamamoto, Y., Tsunedomi, R. and Oka, M. (2008) Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci, 99, 659-65.
97. Vivekanandan, P. and Singh, O.V. (2008) Highdimensional biology to comprehend hepatocellular carcinoma. Expert Rev Proteomics, 5, 45-60.
98. Rhodes, D.R. and Chinnaiyan, A.M. (2005) Integrative analysis of the cancer transcriptome. Nat Genet, 37 (Suppl), S31-37.
99. Rhodes, D.R., Kalyana-Sundaram, S., Mahavisno, V. et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles. Neoplasia, 9, 166-80.
100. Rhodes, D.R., Yu, J., Shanker, K. et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia, 6, 1-6.
101. Rhodes, D.R., Kalyana-Sundaram, S., Tomlins, S.A. et al. (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia, 9, 443-54.
102. Hsu, C.N., Lai, J.M., Liu, C.H. et al. (2007) Detection of the inferred interaction network in hepatocellular carcinoma from EHCO (Encyclopedia of Hepatocellular Carcinoma genes Online). BMC Bioinformatics, 8, 66.
103. Su, W.H., Chao, C.C., Yeh, S.H., Chen, D.S., Chen, P.J. and Jou, Y.S. (2007) OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res, 35, D727-31.
104. Thorgeirsson, S.S., Lee, J.S. and Grisham, J.W. (2006) Functional genomics of hepatocellular carcinoma. Hepatology, 43, S145-50.
105. Ueda, K., Clark, D.P., Chen, C.J., Roninson, I.B., Gottesman, M.M. and Pastan, I. (1987) The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem, 262, 505-8.
106. Mimeault, M., Hauke, R. and Batra, S.K. (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther, 83, 673-91.
107. Okabe, M., Unno, M., Harigae, H. et al. (2005) Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun, 333, 754-62.
108. Thomas, J., Wang, L., Clark, R.E. and Pirmohamed, M. (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104, 3739-45.
109. Ciarimboli, G., Ludwig, T., Lang, D. et al. (2005) Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol, 167, 1477-84.
110. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T. and Inui, K. (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther, 319, 879-86.
111. Zhang, S., Lovejoy, K.S., Shima, J.E. et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res, 66, 8847-57.
112. Okabe, M., Szakacs, G., Reimers, M.A. et al. (2008) Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther, 7, 3081-91.
113. Vavricka, S.R., Jung, D., Fried, M., Grutzner, U., Meier, P.J. and Kullak-Ublick, G.A. (2004) The human organic anion transporting polypeptide 8 (SLCO1B3) gene is transcriptionally repressed by hepatocyte nuclear factor 3beta in hepatocellular carcinoma. J Hepatol, 40, 212-18.
114. Crossman, L.C., Druker, B.J., Deininger, M.W., Pirmohamed, M., Wang, L. and Clark, R.E. (2005) hOCT 1 and resistance to imatinib. Blood, 106, 1133-34; author reply 4.
115. Kantarjian, H.M., Talpaz, M., O’Brien, S. et al. (2003) Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood, 101, 473-75.
116. Cole, S.P., Bhardwaj, G., Gerlach, J.H. et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-54.
117. Doyle, L.A., Yang, W., Abruzzo, L.V. et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 95, 15665-70.
118. Annereau, J.P., Szakacs, G., Tucker, C.J. et al. (2004) Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol, 66, 1397-405.
119. Gillet, J.P., Efferth, T., Steinbach, D. et al. (2004) Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res, 64, 8987-93.
120. Huang, Y., Anderle, P., Bussey, K.J. et al. (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res, 64, 4294-301.
121. Liu, Y., Peng, H. and Zhang, J.T. (2005) Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol, 68, 430-38.
122. Langmann, T., Mauerer, R., Zahn, A. et al. (2003) Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem, 49, 230-38.
123. Szakacs, G., Annereau, J.P., Lababidi, S. et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129-37.
124. Langmann, T., Mauerer, R. and Schmitz, G. (2006) Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin Chem, 52, 310-13.
125. Efferth, T., Gillet, J.P., Sauerbrey, A. et al. (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther, 5, 1986-94.
126. Gillet, J.P., Schneider, J., Bertholet, V., de Longueville, F., Remacle, J. and Efferth, T. (2006) Microarray expression profiling of ABC transporters in human breast cancer. Cancer Genomics Proteomics, 3, 97-106.
127. Steinbach, D., Gillet, J.P., Sauerbrey, A. et al. (2006) ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res, 12, 4357-63.
128. Ross, D.D. (2000) Novel mechanisms of drug resistance in leukemia. Leukemia, 14, 467-73.
129. van den Heuvel-Eibrink, M.M., Sonneveld, P. and Pieters, R. (2000) The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther, 38, 94-110.
130. Hirose, M., Hosoi, E., Hamano, S. and Jalili, A. (2003) Multidrug resistance in hematological malignancy. J Med Invest, 50, 126-35.
131. Marie, J.P. and Legrand, O. (1999) MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol, 457, 1-9.
132. Wuchter, C., Leonid, K., Ruppert, V. et al. (2000) Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica, 85, 711-21.
133. Tafuri, A., Gregorj, C., Petrucci, M.T. et al. (2002) MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 100, 974-81.
134. Wattel, E., Lepelley, P., Merlat, A. et al. (1995) Expression of the multidrug resistance P glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia, 9, 1870-74.
135. Suvannasankha, A., Minderman, H., O’Loughlin, K.L. et al. (2004) Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol, 127, 392-98.
136. Steinbach, D., Wittig, S., Cario, G. et al. (2003) The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 102, 4493-98.
137. Larkin, A., O’Driscoll, L., Kennedy, S. et al. (2004) Investigation of MRP-1 protein and MDR-1P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer, 112, 286-94.
138. Leonessa, F. and Clarke, R. (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer, 10, 43-73.
139. Burger, H., Foekens, J.A., Look, M.P. et al. (2003) RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin Cancer Res, 9, 827-36.
140. Faneyte, I.F., Kristel, P.M., Maliepaard, M. et al. (2002) Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res, 8, 1068-74.
141. Kanzaki, A., Toi, M., Nakayama, K. et al. (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res, 92, 452-58.
142. Robey, R.W., Polgar, O., Deeken, J., To, K.W. and Bates, S.E. (2007) ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev, 26, 39-57.
143. Vitale, M., Rezzani, R., Rodella, L. et al. (1998) HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res, 58, 737-42.
144. Schatton, T., Murphy, G.F., Frank, N.Y. et al. (2008) Identification of cells initiating human melanomas. Nature, 451, 345-49.
145. Alkatout, I., Kabelitz, D., Kalthoff, H. and Tiwari, S. (2008) Prowling wolves in sheep’s clothing: the search for tumor stem cells. Biol Chem, 389, 799-11.
146. Efferth, T. and Volm, M. (2005) Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther, 107, 155-76.
147. Deeken, J.F., Figg, W.D., Bates, S.E. and Sparreboom, A. (2007) Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs, 18, 111-26.
148. Cascorbi, I. (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther, 112, 457-73.
149. Ieiri, I., Takane, H. and Otsubo, K. (2004) The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet, 43, 553-76.
150. Choudhuri, S. and Klaassen, C.D. (2006) Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol, 25, 231-59.
151. Hoffmeyer, S., Burk, O., von Richter, O. et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-78.
152. Kim, R.B., Leake, B.F., Choo, E.F. et al. (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 70, 189-99.
153. Gerloff, T., Schaefer, M., Johne, A. et al. (2002) MDR1 genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br J Clin Pharmacol, 54, 610-16.
154. Nakamura, T., Sakaeda, T., Horinouchi, M. et al. (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther, 71, 297-303.
155. Siegmund, W., Ludwig, K., Giessmann, T. et al. (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther, 72, 572-83.
156. Marzolini, C., Paus, E., Buclin, T. and Kim, R.B. (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther, 75, 13-33.
157. Cascorbi, I. (2006) Genetic basis of toxic reactions to drugs and chemicals. Toxicol Lett, 162, 16-28.
158. Kirchheiner, J., Fuhr, U. and Brockmoller, J. (2005) Pharmacogenetics-based therapeutic recommendations -ready for clinical practice? Nat Rev Cancer, 4, 639-47.
159. Conseil, G., Deeley, R.G. and Cole, S.P. (2005) Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genomics, 15, 523-33.
160. Giacomini, K.M., Brett, C.M., Altman, R.B. et al. (2007) The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther, 81, 328-45.
161. Niemi, M. (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics, 8, 787-802.
162. Letschert, K., Keppler, D. and Konig, J. (2004) Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics, 14, 441-52.
163. Smith, N.F., Marsh, S., Scott-Horton, T.J. et al. (2007) Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther, 81, 76-82.
164. Peltekova, V.D., Wintle, R.F., Rubin, L.A. et al. (2004) Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet, 36, 471-75.
165. Tokuhiro, S., Yamada, R., Chang, X. et al. (2003) An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet, 35, 341-48.
166. Wang, D.S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H. and Sugiyama, Y. (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther, 302, 510-15.
167. Kimura, N., Masuda, S., Tanihara, Y. et al. (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet, 20, 379-86.
168. Orina, J.N., Calcagno, A.M., Wu, C.-P. et al. (2009) Evaluation of current methods used to analyze the expression profiles of ABC transporters yields an improved drug-discovery database. Mol Cancer Ther, 8, 2057-66.